Abstract Biomarker research for cancer diagnosis and prognosis has rapidly expanded technologically and thematically, along with advancements in molecular diagnostics, liquid biopsy, immunotherapy, and artificial intelligence (AI)-based technologies. However, few studies have systematically structured these technological transitions and research framework changes using time-series analyses.